Department of Radiotherapy, Ghent University Hospital, Ghent, Belgium.
Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1045-55. doi: 10.1016/j.ijrobp.2010.03.028. Epub 2010 Jul 17.
To investigate the feasibility of adaptive intensity-modulated radiation therapy (IMRT) using dose painting by numbers (DPBN) for head-and-neck cancer.
Each patient's treatment used three separate treatment plans: fractions 1-10 used a DPBN ([(18)-F]fluoro-2-deoxy-D-glucose positron emission tomography [(18)F-FDG-PET]) voxel intensity-based IMRT plan based on a pretreatment (18)F-FDG-PET/computed tomography (CT) scan; fractions 11-20 used a DPBN plan based on a (18)F-FDG-PET/CT scan acquired after the eighth fraction; and fractions 21-32 used a conventional (uniform dose) IMRT plan. In a Phase I trial, two dose prescription levels were tested: a median dose of 80.9 Gy to the high-dose clinical target volume (CTV(high_dose)) (dose level I) and a median dose of 85.9 Gy to the gross tumor volume (GTV) (dose level II). Between February 2007 and August 2009, 7 patients at dose level I and 14 patients at dose level II were enrolled.
All patients finished treatment without a break, and no Grade 4 acute toxicity was observed. Treatment adaptation (i.e., plans based on the second (18)F-FDG-PET/CT scan) reduced the volumes for the GTV (41%, p = 0.01), CTV(high_dose) (18%, p = 0.01), high-dose planning target volume (14%, p = 0.02), and parotids (9-12%, p < 0.05). Because the GTV was much smaller than the CTV(high_dose) and target adaptation, further dose escalation at dose level II resulted in less severe toxicity than that observed at dose level I.
To our knowledge, this represents the first clinical study that combines adaptive treatments with dose painting by numbers. Treatment as described above is feasible.
研究基于数字剂量描绘(DPBN)的自适应调强放疗(IMRT)对头颈部癌症的可行性。
每位患者的治疗均使用三个单独的治疗计划:第 1-10 次分次采用基于预处理 [(18)-F]氟代-2-脱氧-D-葡萄糖正电子发射断层扫描(FDG-PET)/计算机断层扫描(CT)扫描的 DPBN(18)F-FDG-PET 体素强度的 IMRT 计划;第 11-20 次分次采用基于第 8 次分次后采集的 DPBN 计划;第 21-32 次分次采用常规(均匀剂量)IMRT 计划。在 I 期试验中,测试了两种剂量处方水平:高剂量临床靶区(CTV(high_dose))中位数剂量为 80.9Gy(剂量水平 I)和大体肿瘤体积(GTV)中位数剂量为 85.9Gy(剂量水平 II)。2007 年 2 月至 2009 年 8 月,剂量水平 I 入组 7 例患者,剂量水平 II 入组 14 例患者。
所有患者均无中断完成治疗,未观察到 4 级急性毒性。治疗适应性(即基于第二次 FDG-PET/CT 扫描的计划)使 GTV(41%,p=0.01)、CTV(high_dose)(18%,p=0.01)、高剂量计划靶区(14%,p=0.02)和腮腺(9-12%,p<0.05)的体积减小。由于 GTV 远小于 CTV(high_dose)和靶区适应性,在剂量水平 II 进一步提高剂量导致的毒性比剂量水平 I 观察到的毒性更轻。
据我们所知,这是第一项结合自适应治疗和数字剂量描绘的临床研究。上述治疗是可行的。